Pharmaceutical manufacturer Granules India announced a dramatic jump in first-quarter earnings on Tuesday, with profits climbing nearly 60% as the company’s complex generics business saw margin improvements.
For the three-month period ending June 30, the company’s consolidated net profit reached 1.8 billion rupees — equivalent to approximately $18.71 million — a significant increase from the 1.13 billion rupees posted during the same quarter a year ago. The prior-year figure had been weighed down by a one-time charge.
Several factors shaped the quarterly results:
Total revenue from operations grew 22%, reaching 14.77 billion rupees, fueled by stronger sales of finished pharmaceutical products.
The company credited the profit improvement to a more favorable mix of products sold, which helped expand margins and counterbalance a 17% rise in overall expenses.
In the year-ago quarter, Granules India had recorded a one-time charge of 259.1 million rupees connected to its purchase of Senn Chemicals and the resolution of certain legal matters.
The company holds roughly 30% of the worldwide market for paracetamol and runs 10 manufacturing facilities globally — seven located in India, two in the United States, and one in Europe.
Analysts at Choice Equity Broking projected continued revenue growth, pointing to strong demand for the company’s peptide and contract manufacturing drugs. They also identified Granules India’s oncology product launch pipeline and pending U.S. FDA approvals as key areas investors will be watching closely.
Following the earnings announcement, shares of the company climbed as much as 3.2%.
(Note: $1 = 96.2250 Indian rupees at time of reporting)
